Finland
Every company in the roster headquartered in Finland.
Every company in the roster headquartered in Finland.
3 of 3 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Orion CorporationORNBV · Nasdaq Helsinki | 2 assets: 1 approved, 1 Ph 3 | LevosimendanPhase 3 · Heart FailurePartial signal | 30 Jun 2028Levosimendan · Phase 3 | — | $189MDec 2025 | — | $239M |
TILT Biotherapeutics Ltd.Private | 1 asset: 1 Ph 1 | Igrelimogene litadenorepvecPhase 1 · Non-Small Cell Lung Cancer | Nov 2026Igrelimogene litadenorepvec · Phase 1 | — | — | — | — |
Valo Therapeutics OyPrivate | 1 asset: 1 Ph 1 | PeptiCRAd-1Phase 1 · Non-Small Cell Lung Cancer | 30 Apr 2027PeptiCRAd-1 · Phase 1 | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.